Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of caspofungin prophylaxis for invasive fungal infections in acute leukemia during induction chemotherapy
2006-004432-70Phase 2Active
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Nov 2006
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of caspofungin in invasive mycoses, invasive aspergillosis (IA) and candidiasis, sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Overall clinical yield of caspofungin prophylaxis. Started Nov 2006; status: active.
02
Drugs
caspofungin
03
Conditions
invasive mycosesinvasive aspergillosis (IA)candidiasis
Beyond the preview
Go deeper on 2006-004432-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004432-70.